Dr. Yu began by highlighting that moderately hypofractionated IMRT (MH-IMRT) has been the standard of care for prostate cancer since RTOG 0415 and other landmark studies. 1 At the time this trial was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback